“…Inhibitors of PTP1B can reduce the resistance to insulin and due to enhanced insulin signaling increase the insulin-stimulated glucose uptake. Therefore, PTP1B inhibitors could be used as pharmaceuticals for the treatment of type 2 diabetes and obesity [8,18,19,20]. Metabolites belonging to a broad spectrum of compound classes—including terpenoids, phenolic compounds, alkaloids, as well as semi-synthetic compounds and derivatives thereof, i.e., kinsensoide, lobaric acid, and oleanolic acid—have been patented as promising PTP1B inhibitors [21].…”